Renal failure after high-dose methotrexate in a child homozygous for MTHFR C677T polymorphism

Pediatric Blood and Cancer

Volumn 50, Issue 1, 2008, Pages 154-156

  Turello, Rita ^a   Rentsch, Katharina ^b   Di Paolo, Ermindo ^a   Popovic, Maja Beck ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

High dose methotrexate; Methotrexate (MTX) toxicity; MTHFR polymorphism; Renal failure

Indexed keywords

METHOTREXATE;

ANAMNESIS; ARTICLE; CASE REPORT; DNA POLYMORPHISM; DRUG MEGADOSE; FEMALE; GENE; GENETIC ANALYSIS; GENOTYPE; HOMOZYGOSITY; HUMAN; KIDNEY FAILURE; MEDIASTINUM; MTHFR GENE; PRIORITY JOURNAL; SCHOOL CHILD; T CELL LYMPHOMA;

ANTIMETABOLITES, ANTINEOPLASTIC; CHILD; FEMALE; HOMOZYGOTE; HUMANS; KIDNEY FAILURE, ACUTE; LYMPHOMA, T-CELL; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC;

EID: 36849086344     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21176     Document Type: Article

References (18)

1. Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42:1322-1329.
2. Masson E, Relling MV, Synold TW, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. J Clin Invest 1996;97:73-80.
3. Ferguson WS, Goorin AM. Current treatment of osteosarcoma. Cancer Invest 2001;19:292-315.
4. Abelson HT, Fosburg MT, Beardsley GP, et al. Methotrexate-induced renal impairment: Clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. J Clin Oncol 1983;1:208-216.
5. Takami M, Kuniyoshi Y, Oomukai T, et al. Severe complications after high-dose methotrexate treatment. Acta Oncol 1995;34:611-612.
6. Ueland PM, Steinar H, Schneede J, et al. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201. Review.
7. Chiusolo P, Reddiconto G, Casorelli I, et al. Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. Ann Oncol 2002;13:1915-1918.
8. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004;5:819-834.
9. Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001;98:231-234.
10. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylene tetrahydrofolate reductase were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2000;12:183-190.
11. Toffoli G, Russo A, Innocenti F, et al. Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 2003;103:294-299.
12. Strunk T, Goottschalk S, Goepel W, et al. Subacute leukencephalopathy after low-dose intrathecal methotrexate in an adolescent heterozygous for the MTHFR C677T polymorphism. Med Pediatr Oncol 2003;40:48-50.
13. Abelson HT, Ensminger W, Rosowsky A, et al. Comparative effects of citrovorum factor and carboxypeptidase G1 on cerebrospinal fluid-methotrexate pharmacokinetics. Cancer Treat Rep 1978;62:1549-1552.
14. Adamson PC, Balis FM, McCully CL, et al. Methotrexate pharmacokinetics following administration of recombinant carboxypeptidase-G2 in rhesus monkeys. J Clin Oncol 1992;10:1359-1364.
15. Mohty M, Peyriere H, Guinet C, et al. Carboxypeptidase G2 rescue in Delayed methotrexate elimination in renal failure. Leuk Lymphome 2000;37:441-443.
16. DeAngelis LM, Tong WP, Lin S, et al. Carboxypeptidase G2 rescue after high-dose methotrexate. J Clin Oncol 1996;14:2145-2149.
17. Ksiazek P, Bednarek-Skublewska A, Buraczyn'ska M. The C677T methylenetetrahydrofolate reductase gene mutation and nephropathy in type 2 diabetes mellitus. Med Sci Monit 2004;10:BR47-BR51.
18. Yuichiro Makita MD, Dariusz K, Moczulski MD, et al. Methylenetetrahydrofolate reductase gene polymorphism and susceptibility to diabetic nephropathy in type 1 diabetes. Am J Kidney Dis 2003;41:1189-1194.